-
Clinical Trials & Development4 days agoM3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
International Council on Harmonisation - Joint Safety/Efficacy (Multidisciplinary)
-
Clinical Trials & Development4 days agoTyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage...
-
Clinical Trials & Development4 days agoNovo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase...
-
Clinical Trials & Development4 days agoDiverse Patients Share Views on Hypertension Care in Safety-Net Settings
Hypertension is one of the most common and most consequential chronic conditions in the United States, yet for millions of low-income, immigrant, and multilingual patients, the...
-
Clinical Trials & Development4 days agoBioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts
With a phase 3 win now fleshed out and an FDA filing recently submitted, BioMarin is advancing expansion plans for Voxzogo, looking to extend the dwarfism...
-
Clinical Trials & Development4 days ago
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But...
-
Clinical Trials & Development5 days ago
Beeline flies into phase 3 as oral lupus drug soars past placebo
A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
-
Clinical Trials & Development5 days ago
StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in Patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke
OSAKA, Japan, September 9, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the results of...
-
Clinical Trials & Development5 days ago
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail
Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
-
Clinical Trials & Development5 days agoNovartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial
Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT)...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
